AAV2 expression vector of mito-SRAI (signal-retaining autophagy indicator) driven by the tetracyclin-responsive element promoter for quantitative visualizing mitophagy.
![]() Drawn by SnapGene® software |
|
| Clone info. | AAV2 expression vector of mito-SRAI (signal-retaining autophagy indicator) driven by the tetracyclin-responsive element (TRE-tight) promoter. mito-SRAI is a fluorescent sensor for quantitative visualizing mitophagy. SRAI is a tandem fusion of YPet and TOLLES, fused with a DNA linker that encodes a triple repeat of the amino acid linker Gly-Gly-Gly-Gly-Ser. The ITRs (inverted terminal repeats) are derived from AAV serotype 2. |
|---|---|
| Comment | Expression was confirmed by the depositor, co-transfection to cultured cell with a plasmid vector that expresses tTA under ubiquitous promoter. |
| Vector backbone | plasmid |
| Selectable markers | Ampicillin |
| Growth conditions | LB+Amp, 37oC |
| Gene/insert name | Aequorea victoria YPet (GFP) cDNA Galaxea fascicularis TOLLES (GFP) cDNA |
| Depositor|Developer | Miyawaki, Atsushi | Hioki, Hiroyuki | Katayama, Hiroyuki | |
Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
| Ordering forms | Order form [Credit Card Payment MTA, for use for not-for-profit academic purpose [Word Please visit Information of Request for Distribution.[link] |
|---|---|
| Terms and conditions for distribution | 1. If the BIOLOGICAL RESOURCE is to be used by a for-profit organization, the RECIPIENT must agree with RIKEN Innovation Co., Ltd. on the terms and conditions of its use. For inquiries, please contact: license-contact@innovation-riken.jp 2. The RECIPIENT’s Scientist agrees not to transfer the BIOLOGICAL RESOURCE and its derivatives to any third party including any resource center without the prior written consent of DEPOSITOR. 3. When publishing the research results obtained using the BIOLOGICAL RESOURCE, a citation to the literature specified by the DEPOSITOR or an acknowledgement to the DEPOSITOR is requested. Sohn, J. et al., PLoS One, 12 (1): e0169611 (2017). Hioki, H. et al., Neurosci. Res., 63 (2): 149-154 (2009). Katayama et al. Cell 181, 1176–1187 (2020). |
| Remarks | Remember that you will be working with samples containing infectious virus. |
[open/close]| 必要書類 | 提供依頼書 提供同意書 (MTA, 非営利学術目的用)[Word 手続きの概要は、「提供申込みについて[link]」をご覧ください。 |
|---|---|
| MTAに書く使用条件 | 1. If the BIOLOGICAL RESOURCE is to be used by a for-profit organization, the RECIPIENT must agree with RIKEN Innovation Co., Ltd. on the terms and conditions of its use. For inquiries, please contact: license-contact@innovation-riken.jp 2. The RECIPIENT’s Scientist agrees not to transfer the BIOLOGICAL RESOURCE and its derivatives to any third party including any resource center without the prior written consent of DEPOSITOR. 3. When publishing the research results obtained using the BIOLOGICAL RESOURCE, a citation to the literature specified by the DEPOSITOR or an acknowledgement to the DEPOSITOR is requested. Sohn, J. et al., PLoS One, 12 (1): e0169611 (2017). Hioki, H. et al., Neurosci. Res., 63 (2): 149-154 (2009). Katayama et al. Cell 181, 1176–1187 (2020). |
| 備考 | このリソースはウイルス粒子産生用のため、取扱いに注意が必要です。 |
| Catalog # | Resource name | Shipping form | Fee |
|---|---|---|---|
| RDB18684 | pAAV2-TRE-mito-SRAI-BGHpA | DNA solution |
Materials & Methods section:
| The pAAV2-TRE-mito-SRAI-BGHpA was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB18684). |
Reference section:
| Katayama, H., Hama, H., Nagasawa, K., Kurokawa, H., Sugiyama, M., Ando, R., Funata, M., Yoshida, N., Homma, M., Nishimura, T., Takahashi, M., Ishida, Y., Hioki, H., Tsujihata, Y., Miyawaki, A., Visualizing and Modulating Mitophagy for Therapeutic Studies of Neurodegeneration. Cell 181(5): 1176-1187 (2020). PMID 32437660. [PubMed] [Article] [RRC of NBRP] |
Further references such as user reports and related articles (go to bottom)
Original, user report and related articles
| original | Katayama, H., Visualizing and Modulating Mitophagy for Therapeutic Studies of Neurodegeneration. Cell 181(5): 1176-1187 (2020). PMID 32437660. [PubMed] [Article] [RRC of NBRP] |
|---|
Featured content